Aerie Pharmaceuticals Inc. (AERI)

18.93
0.70 3.80
NASDAQ : Health Technology
Prev Close 18.23
Open 18.35
Day Low/High 18.30 / 19.19
52 Wk Low/High 17.51 / 50.10
Volume 684.32K
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 46.32M
Market Cap 874.54M
EPS -5.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

Aerie Pharmaceuticals Announces New Hires

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces FDA Acceptance Of NDA Submission For Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Apple.

Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

Short Interest Drops 11.4% For AERI

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 404,472 share decrease in total short interest for Aerie Pharmaceuticals Inc , to 3,133,233, a decrease of 11.43% since 03/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Aerie Pharmaceuticals To Announce First Quarter 2017 Financial Results And Host Conference Call On Tuesday, May 2, 2017

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), (the "Company"), announced today that its first quarter 2017 financial results will be released after the market closes on Tuesday, May 2, 2017.

Aerie Pharmaceuticals Announces Appointment Of Raymond S. Wysmierski As Director Of Compliance

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety And Efficacy Results For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Expansion Of Commercialization Team

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals To Present At The 16th Annual Needham Healthcare Conference

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

Aerie Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Business Update

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and...

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.

Aerie Pharmaceuticals To Present At Three Investor Conferences In March

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Resubmission Of NDA For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals To Announce Fourth Quarter And Year End 2016 Financial Results And Host Conference Call On Tuesday, March 7, 2017

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), (the "Company"), announced today that its fourth quarter and year end 2016 financial results will be released after the market closes on Tuesday, March 7, 2017.

Aerie Pharmaceuticals To Present At The RBC Capital Markets 2017 Global Healthcare Conference

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Noteworthy Monday Option Activity: AERI, NHTC, SUPN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Aerie Pharmaceuticals Inc , where a total volume of 1,457 contracts has been traded thus far today, a contract volume which is representative of approximately 145,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 53.5% of AERI's average daily trading volume over the past month, of 272,235 shares.

Aerie Pharmaceuticals Announces Appointment Of Huan Sheng, M.D., Ph.D., As Director Clinical Research And Drug Safety

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Aerie Pharmaceuticals Announces Appointment Of Barry Ivin As Site Director Of New Manufacturing Plant In Ireland

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Dearth of Momentum Helps Build 'Wall of Worry'

Dearth of Momentum Helps Build 'Wall of Worry'

Despite sluggishness, bears are not able to produce any real selling pressure.

Aerie Pharmaceuticals Announces Appointment Of Kristine Erickson, O.D., Ph.D., As Vice President Clinical Research

Aerie Pharmaceuticals Announces Appointment Of Kristine Erickson, O.D., Ph.D., As Vice President Clinical Research

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Allergan, Apple, Facebook: Doug Kass' Views

Allergan, Apple, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.

Allergan, Citigroup, Apple: Doug Kass' Views

Allergan, Citigroup, Apple: Doug Kass' Views

Doug Kass shares his thoughts on how he had one of his best days in recent memory, and warns you not to look in the rear view mirror.

Aerie Pharmaceuticals Enters Into Lease Agreement For New Manufacturing Plant In Ireland

Aerie Pharmaceuticals Enters Into Lease Agreement For New Manufacturing Plant In Ireland

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

Inotek Pharma Shares Plummet Following Negative Glaucoma Trial Results

Inotek Pharma Shares Plummet Following Negative Glaucoma Trial Results

Shares of Inotek Pharma plummeted Tuesday after saying that its Phase 3 clinical trial for the treatment of glaucoma did not "achieve superiority to the placebo."

Inotek Pharma Glaucoma Drug Suffers Study Setback at Start of New Year

Inotek Pharma Glaucoma Drug Suffers Study Setback at Start of New Year

The Lexington, Mass.-based biotech company said Tuesday that an experimental treatment for glaucoma failed to fully demonstrate superiority over placebo in a phase III clinical trial.

Aerie Pharmaceuticals Provides Update On Timing Of NDA Filing For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals Provides Update On Timing Of NDA Filing For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of...

TheStreet Quant Rating: D- (Sell)